NCT06575075View on ClinicalTrials.gov

Pilot Study of RR-HNK in OCD

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2029

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

RR-HNK/Hydroxynorketamine

(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.

DRUG

Placebo

Sterile Saline

Trial Locations (1)

94305

RECRUITING

Stanford University School of Medicine, Palo Alto

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Carolyn Rodriguez

OTHER